Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

FDA Grants Fast Track Designation to PSV359 for Advanced FAP-Positive Solitary Fibrous Tumors

9 October 2026 · By · Wire by Fusion42

Published

9 October 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at onclive.com →

◆ Verified

Fusion42 · 9 October 2026 · Fusion42 review

The FDA has granted fast track designation to PSV359 for treating adults with locally advanced unresectable or metastatic FAP-positive solitary fibrous tumors, aiming to expedite its development and review.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You can now target FAP-positive tumors with a drug on a faster path through the FDA, which is rare for such specific cancer therapies. Prepare to navigate a niche clinical space that could broaden patient options and speed your product’s approval timeline.

◆ Coverage

1 source · 9 Oct 2026

◆ Related on Wire

◆ Topics

Biotechfdafast-trackbiotechradiopharmaceuticaloncologyclinical-trial